Skip to main content
    O

    OS Therapies Incorporated (OSTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.41
    +0.01 (+1.08%)

    Market Cap: $65.06M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    13%(1/8)
    Avg Surprise
    -67.62%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.16 - $-0.10
    3 analysts
    EPS RevisionsNo revisions (7d)
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.15+20.0%
    60d ago$-0.20+39.0%
    30d ago$-0.10-20.0%
    7d ago$-0.120.0%
    Current$-0.12
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.21 - $-0.10
    3 analysts
    Revenue Consensus
    $-242750
    Range$-242750 - $-242750
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.12---
    Jun 26
    Reported Aug 14
    		$-0.20$-0.25+20.00%Beat-5.3%
    Mar 26
    Reported May 18
    		$-0.27$-0.19-42.11%Miss-50.0%
    Dec 25
    Reported Mar 31
    		$-0.41$-0.14-192.86%Miss-115.8%
    Sep 25
    Reported Nov 14
    		$-0.21$-0.12-75.00%Miss-16.7%
    Jun 25
    Reported Aug 19
    		$-0.19$-0.15-26.67%Miss+68.9%
    Mar 25
    Reported May 15
    		$-0.18$-0.11-63.64%Miss-
    Dec 24
    Reported Mar 31
    		$-0.19$-0.14-35.71%Miss-
    Sep 24
    Reported Nov 15
    		$-0.18$-0.08-125.00%Miss-
    Jun 24
    Reported Aug 14
    		$-0.61N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.29EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-914.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.18xQuick Ratio0.18x
    Trading Statistics
    Beta-0.64Avg Volume815.85K
    52-Week High$2.2552-Week Low$1.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.53
    SMA 20$1.60
    SMA 50$1.64
    SMA 200$1.58
    EMA 10$1.51
    EMA 20$1.57
    EMA 50$1.62
    EMA 200$1.64

    MACD

    Line: -0.06Signal: -0.04Hist: -0.02

    ADX

    ADX: 11.4+DI: 18.9-DI: 26.7

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down100.0
    PSAR$1.64

    Bollinger Bands

    Upper Band$1.81
    Lower Band$1.39
    %B Position2637%(Upper)
    Band Width0.04

    RSI (14-Day)

    Neutral
    34.4

    Momentum Oscillators

    Stoch %K3.7
    Stoch %D13.1
    Williams %R-91.8
    ROC (10d)-12.7%
    Momentum-0.20
    CCI (20d)-192.4
    MFI (14d)11.4

    Volatility Measures

    ATR (14d)$0.10(7.2%)
    StdDev (20d)0.11
    Hist Vol52.2%(High)

    Volume Flow

    VWAP$1.41
    OBV-17.6M
    AD Line-29.1M
    CMF (20d)-0.579

    Volume Metrics

    Avg Vol (20d)764.8K
    Vol Ratio0.5x(Low)
    VWMA (20d)$1.56

    Pivot Points

    R3$1.55
    R2$1.52
    R1$1.45
    Pivot Point$1.42
    S1$1.35
    S2$1.32
    S3$1.25

    Advanced Oscillators

    TSI-19.19
    Ultimate Osc33.2
    KST-83.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$124,938$0$0$0$1,390$0$0$0N/A$0
    Gross Profit$0$0$-124,938$0$0$0$-1,390$0$0$0N/A$0
    Operating Expenses$8.58M$10.17M$11.99M$6.88M$4.84M$5.00M$2.97M$2.44M$779,800$630,232$1.16M$622,208
    R&D$6.07M$7.35M$8.80M$3.76M$2.50M$1.31M$870,468$1.21M$396,567$361,809$1.02M$454,505
    SG&A$2.50M$2.82M$3.19M$3.12M$2.34M$3.69M$2.10M$1.23M$383,233$268,423$141,285$167,703
    Operating Income$-8,575,612$-10,167,938$-11,987,892$-6,879,595$-4,838,728$-4,999,486$-2,966,421$-2,437,393$-779,800$-630,232$-1,157,033$-622,208
    Interest Income$46$45$54$65$64$66$-1$0$1$0$0$1
    Interest Expense$5,581$75,344$1.47M$0$0$0$7,559$437,839$777,681$828,760$307,534$1.35M
    Income Before Tax$-8,632,386$-10,396,831$-13,460,833$-6,879,530$-4,536,622$-3,876,859$-2,991,234$-2,875,232$-1,557,480$-1,458,992$-1,464,566$-1,974,990
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,632,386$-10,396,831$-13,460,833$-6,879,530$-4,536,622$-3,876,859$-2,991,234$-2,875,232$-1,557,480$-1,458,992$-1,464,566$-1,974,990
    EBITDA$-8,496,804$-10,127,622$-12,298,318$-6,754,657$-4,424,172$-3,876,230$-2,982,284$-2,099,104$-270,451$-50,801$-943,798$362,250
    EBIT$-8,626,851$-10,321,532$-13,460,887$-6,879,595$-4,536,686$-3,876,925$-2,983,674$-2,437,393$-779,800$-630,232$-1,157,033$-622,208
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OSTX

    News

    OS Dives

    OS Therapies, Inc. (NYSE: OSTX) shares fell sharply after the company provided a regulatory update regarding its Biologics License Application (BLA) for OST-HER2 with the FDA. The company is seeking accelerated approval...

    Baystreet.ca•10/9/26•Bearish

    Rubenstein Public Relations Named Agency of Record for OS Therapies

    Rubenstein Public Relations (RPR) has been appointed as the Agency of Record for OS Therapies, a clinical-stage oncology company specializing in gene-edited...

    GlobeNewswire•10/9/26•Bullish

    PR News | Accounts in Transit: Rubenstein PR Picks Up OS Therapies - Thu., Oct. 8, 2026

    Rubenstein Public Relations has been named the agency of record for OS Therapies, a company specializing in gene-edited cancer immunotherapies...

    O'Dwyer's PR News•10/8/26•Bullish

    Rubenstein Public Relations Named Agency of Record for OS Therapies

    Rubenstein Public Relations (RPR) has been appointed as the Agency of Record for OS Therapies, a clinical-stage oncology company specializing in gene-edited...

    The Manila Times•10/8/26•Bullish

    OS Therapies appoints Rubenstein PR to lead global communications for its cancer immunotherapy advances

    OS Therapies, a clinical-stage oncology company focusing on gene-edited cancer immunotherapies, has appointed Rubenstein Public Relations as its Agency of Record for global communications. This partnership aims...

    Pluang•10/8/26•Neutral

    OSTX Valuation and Fair Value

    P/E
    -1.3x
    Forward P/E
    1.7x
    P/B
    -5.4x
    See GNG's fair value

    OSTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -914.0%

    OSTX Competitors

    CompanyTicker
    Rein Therapeutics IncRNTX
    ImmunoPrecise Antibodies Ltd.HYFT
    Verrica Pharmaceuticals IncVRCA
    MDxHealth SAMDXH
    XBiotech IncXBIT
    ZEN Graphene Solutions LtdZTEK
    Neumora Therapeutics, Inc.NMRA
    Tenax Therapeutics IncTENX

    Sector: Healthcare

    OSTX Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    OSTX Bull Case vs Bear Case

    Bear case

    • OSTX beat EPS estimates in 12.5% of its last 8 reported quarters.

    OSTX Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -67.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.12
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About OSTX

    Does OSTX pay dividends?

    OS Therapies Incorporated (OSTX) does not currently pay a regular dividend.

    What is OSTX's market cap?

    OS Therapies Incorporated (OSTX) has a market capitalization of $65.06M with a current stock price of $1.41.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In